Margaret Kaczor Andrew: Okay. Thanks guys.
Operator: Thank you. Your next question comes from Ryan Zimmerman of BTIG. Your line is already open.
Unidentified Analyst: Hi, everyone. This is Izzy on for Ryan. Thanks for taking the question. So I heard your comments on the rollout of the initiatives from the Analyst Day. I was just wondering if you could provide some any updates on what you guys have learned from the first month or so of operating the call center and if you’ve seen any tangible benefits from it so far?
Tom Frinzi: Yeah. Thanks for the question. Specifically, it is too early as we indicated to make some broad statements, but we’ve been very encouraged by the activity level. And quite frankly, within one of the markets we generated 18 solid leads that we passed on to practices ready to convert. So it’s encouraging, but it’s way too early to make any determination of the real impact, but the enthusiasm and the activity level is certainly encouraging.
Patrick Williams: And I think importantly the practices especially associated with the US Highway 93 are on board with this. And that’s always one of your concerns when you start doing a call center. But this is something that other companies have done and we’re seeing very good cooperation and partnership with our practices and we expect that to continue.
Unidentified Analyst: Got it. Thank you. And then just transitioning a little bit over to China. So what are you guys seeing from a competitive standpoint right now? And is there anything that we should be looking out for 2024? Thanks for taking the question.
Tom Frinzi: Sure. As we talked about at the Investor Day and I think it came up earlier in some conversations. iBright is a new technology that could come to the market in China. It’s an acrylic base as opposed to a calmer based ICL and we think that could gain approval mid to third quarter of 24%. But again, we think competition coming in is a positive certainly imitation being the highest form of flattery. And we certainly have first-mover advantage with well over 2 million implants sold around the world. And we also have a pricing and market segmentation ready to implement upon competition coming to the marketplace but the real difference is the polymer material that we have pioneered the biocompatibility of it the performance of it from a quality of vision post-operatively gives us continued confidence that even with competition coming we will maintain our first-mover advantage. Operator, please take the next question.
Unidentified Analyst: Great. Thanks for taking the questions.
Brian Moore: Operator, we’ll take the next question.
Operator: Your next question comes from the line of Steve Lichtman. Your line is now open.
Steve Lichtman: Thanks. Good evening guys. You mentioned expanding the rollout of Viva in Europe here post the September meeting. Can you talk a little bit more about what that could look like and what you see as the opportunity as you ramp that?
Tom Frinzi: Yes, Steve, thanks for the question. Again, as I’ve stated before I think it’s important as a business for us to be in the presbyopia channel, if you will even though we’re talking about myopic patients that are suffering from presbyopia early in their stage 45 to 55 years old. So as we met with a group of surgeons in Vienna at the most recent ESCRS meeting in September, we were encouraged by the feedback we received and we’re going to continue to work with a subset of surgeons certainly less than 100 in that marketplace as we continue to refine the positioning both externally and internally of the product. And I think over the coming three-year horizon the EVO Viva will play a role. We have yet to define how big of a role it will play.
Patrick Williams : Yes. And as a reminder we actually did not include any material presbyopia or Viva lens in our three-year CAGR that we put out there at Investor Day.
